Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of an oral probiotic preparation in hidradenitis suppurativa treatment

Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of an oral probiotic preparation in hidradenitis suppurativa treatment

Identifiers

URI: http://hdl.handle.net/10952/6541

Files

6_Clincial experimental dermatology 2023.pdf (1.15 MB)

Publication date

2023-04

Metrics

Abstract

The clinical trial has a randomized, double-blind, placebo-controlled design, which aims to evaluate the effect of an oral probiotic preparation administered for 12 weeks on the evolution of hidradenitis suppurativa

Description

Randomized, double-blind, placebo-controlled clinical trial, to evaluate an oral probiotic effectiveness administered for 12 weeks on the hidradenitis suppurativa evolution. A total of 60 patients diagnosed with hidradenitis suppurativa will participate in the study, who will be randomized into two treatment groups in a 1:1 ratio (30 patients per group). The intervention groups are differentiated according to the treatment to be received: probiotic or placebo of similar appearance, along with standard therapy according to usual clinical practice. The 12 weeks of treatment are structured into three face-to-face visits: Visit 1 (initial; week 0), Visit 2 (intermediate; week 6) and Visit 3 (final; week 12).